The research group of the University of Alcalá in «Dendrimers for biomedical applications» presents the following invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives of these.
Its main field of application is in biomedicine, as non-viral transport agents, as drug transporters, to elaborate a drug, as antimicrobial, antiviral or antipyretic agents.
In the environmental sector we also find its application as biocides for water treatment.
The group seeks to reach license agreements, collaboration or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.
The present invention provides compounds formed by dendrons of carbosilane structure that are functionalized in their periphery with anionic groups (such as carboxylate, sulfonate or sulfate), which endow the system with a net negative charge, or cationic (such as ammonium), which endow the system with a positive net charge.
These dendrons present a focal point that contains a hydrophobic function, mainly derived from a fatty acid. The fatty acid is linked to the dendron preferably through an ester bond, without dismissing other types of bonds, or even through electrostatic interactions.
Another aspect of the present invention relates to the process for obtaining the compounds.
The patent also includes the preparation of Janus type dendrimers, which are characterized by being formed by two dendritic units that have some distinct structural feature.
And finally, the invention includes the ability of the described compounds to form micelles. The principal medium for its formation would be aqueous but micelles can also be formed in solutions containing soluble salts in these media or surfactants.
Regarding the uses in biomedicine of these compounds and the micelles formed by them, it is worth highlighting: their use as non-viral transport agents for the transfection or internalization of nucleic material within different cell lines in gene therapy processes; use of these compounds as "per se" therapeutic agents, for example as antiviral, antimicrobial or antipyretic agents, or as drug transporters, even for the preparation of a drug of solid or liquid composition. And oral, nasal, topical or parenteral administration.
In their environmental application, they can be used as biocides to prevent the appearance of microorganisms on surfaces or water treatment.
These systems are able to overcome some of the difficulties that certain drugs found, allowing to facilitate their transport, favoring their solubility, increasing their solubility and even acting as transporters to the areas of interest.
- Ease of diffusion of dendrimers through biological barriers, and therefore access to target cells.
- Possibility of encapsulation and transport of drugs or other molecules with biological activity.
- The preparation of these dendrimers as pharmaceutical formula can be very varied, being possible any solid composition (tablets, pills, capsules, granules, etc.) or liquid (gels, solutions, suspensions or emulsions). For oral, nasal, topical or parenteral administration.
Intellectual property status
Patent already applied for
Patent application number : The patent has been requested together with the Gregorio Marañón Hospital and responds to the application reference P201600726.
Current development status
Desired business relationship
The research group seeks to reach licensing, collaboration or commercial agreements with technical assistance, with companies in the biomedical, pharmaceutical, biotechnological and environmental sector.